Key result
Double filtration plasmapheresis effectively reduced triglycerides, with a more obvious APACHE II score reduction in patients with baseline triglycerides ≥33.9 mmol/L (P<0.05).
Why the study?
The clinical value of double filtration plasmapheresis (DFPP) in severe hypertriglyceridemia-induced pancreatitis (sHTGP) remains controversial.
Does double filtration plasmapheresis improve clinical outcomes and reduce triglycerides in patients with severe hypertriglyceridemia-induced pancreatitis?
Observational (n=50)
Does double filtration plasmapheresis improve clinical outcomes and reduce triglycerides in patients with severe hypertriglyceridemia-induced pancreatitis?
p-value: p=<0.05
Double filtration plasmapheresis rapidly reduces triglycerides and improves APACHE II scores in severe hypertriglyceridemia-induced pancreatitis, particularly in patients with TG ≥33.9 mmol/L.
BACKGROUND: The value of double filtration plasmapheresis (DFPP) in severe hypertriglyceridemia-induced pancreatitis (sHTGP) is controversial. This study aimed to investigate the efficacy of DFPP on clinical outcomes in patients with sHTGP and the costs associated with the procedure. METHODS: Patients who underwent DFPP after admission between January 2016 and December 2021 were recruited. Data on lipid profile, clinical parameters, and costs were retrospectively collected and analyzed. RESULTS: Fifty sHTGP patients who received DFPP were enrolled. All of the lipid profile were significantly reduced and maintained a downward trend. The APACHE II score on admission was higher and the reduction after DFPP was more obvious (P < 0.05) in patients with higher triglyceride (TG) levels (≥33.9 mmol/L) than in patients with lower TG levels. More material fees were expended in the higher TG group due to more DFPP sessions (P < 0.05), but no significant differences existed in total hospital costs between the two groups. CONCLUSION: DFPP could rapidly and effectively reduce TGs to a safe level. APACHE II score reduction was obvious in patients with TGs ≥33.9 mmol/L and was associated with lipid profile changes. DFPP may benefit sHTGP patients with a TG level higher than the current initiation threshold.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2022) conducted an observational in Severe hypertriglyceridemia-induced pancreatitis (n=50). Double filtration plasmapheresis (DFPP) was evaluated on Lipid profile, clinical parameters (APACHE II score), and costs (p=<0.05). Double filtration plasmapheresis effectively reduced triglycerides, with a more obvious APACHE II score reduction in patients with baseline triglycerides ≥33.9 mmol/L (P<0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: